date in the third quarter of this calendar year. Regulatory submissions for oveporexton are also under review in China and Japan, with additional submissions planned throughout the year. Oveporexton is an investigational compound that has not been approved for use by any regulatory authority.

About the FirstLight and RadiantLight Phase 3 Orexin Studies

FirstLight (TAK-861-3001; NCT06470828) and RadiantLight (TAK-861-3002; NCT06505031) are global, multicenter, placebo-controlled studies to evaluate the efficacy, safety and tolerability of oveporexton compared to placebo in patients with narcolepsy type 1 (NT1) over 12 weeks. The studies were conducted in 19 countries, with enrollment completed within six months. The FirstLight study enrolled 168 participants randomized to one of three dosing arms (twice-daily 2mg, 1mg and placebo). The RadiantLight study enrolled 105 participants randomized to two dosing arms (twice-daily 2mg and placebo). More than 95 percent of the participan
=*=*=*=*=*=
当前为第6/14页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页